Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.

OBJECTIVES:To assess the effectiveness and safety of Chinese herbal medicine (CHM) for the treatment of aspirin resistance (AR). METHODS:A comprehensive research of seven electronic databases was performed for comparative studies evaluating CHM for AR. Two authors independently extracted data and as...

Full description

Bibliographic Details
Main Authors: Hanyu Chen, Zhengjie Shen, Jiandong Chen, Haowen Zhang, Xiaohu Chen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4859478?pdf=render
_version_ 1819232074996908032
author Hanyu Chen
Zhengjie Shen
Jiandong Chen
Haowen Zhang
Xiaohu Chen
author_facet Hanyu Chen
Zhengjie Shen
Jiandong Chen
Haowen Zhang
Xiaohu Chen
author_sort Hanyu Chen
collection DOAJ
description OBJECTIVES:To assess the effectiveness and safety of Chinese herbal medicine (CHM) for the treatment of aspirin resistance (AR). METHODS:A comprehensive research of seven electronic databases was performed for comparative studies evaluating CHM for AR. Two authors independently extracted data and assessed the methodological quality of the included trials using the Cochrane risk of bias tool. Data wasere synthesized by using RevMan 5.3 software. (PROSPERO Registration #CRD42015020182). RESULTS:18 randomized controlled trials (RCTs) involving 1,460 patients were included. 15 RCTs reported significant difference in the reduction of platelet aggregation rate (PAR) induced by adenosine diphosphate (ADP) (P<0.05), and 11 reported significant effect of CHM plus aspirin to reduce PAR induced by arachidonic acid (AA) (P<0.05) compared with aspirin 100mg/d treatment. The pooling data of 3 RCTs showed the thromboxane B2 (TXB2) in patients with CHM plus aspirin versus aspirin were significantly reduced (Random Effect model (RE), Standard Deviation (SD) = -95.93, 95% Confidential Interval (CI)[-118.25,-73.61], P<0.00001). Subgroup analysis showed that TXB2 (Fixed Effect model (FE), SD = -89.23, 95%CI[-121.96,-56.49], P<0.00001) had significant difference in Tongxinluo capsule plus aspirin versus aspirin. 2 RCTs reported the clinical effective rate, and the meta-analysis result showed a significant difference in intervention and control group (FE, Relative Risk (RR) = 1.67, 95%CI[1.15, 2.42], P = 0.007<0.05). In 4 trials, CHM plus aspirin had better effects of reducing the reoccurrence of cerebral infarction than aspirin (FE, RR = 0.24, 95%CI [0.11, 0.49], P<0.0001). And one trial showed that CHM plus aspirin could decrease the National Institutes of Health Stroke Scale (NHISS) score (P<0.05) and increase the Barthel Index (BI) score (P<0.05). 4 trials stated that there were no adverse effects occurred in intervention group, and analysis showed significant difference of CHM or CHM plus aspirin in reducing the occurrence of adverse events (FE, RR = 0.22, 95%CI[0.13, 0.39], P<0.00001). 5 trials claimed that the CHM monotherapy and CHM adjunctive therapy for AR did not add the risk of bleeding (FE, RR = 0.50, 95%CI[0.20, 1.22], P = 0.13>0.05). CONCLUSIONS:CHM may be effective and safe as an alternative and collaborative therapy for AR. However, the current evidence and potential promising findings should be interpreted with caution due to poor and varying methodological quality of included studies and the heterogeneity of interventions. Thus, further exploration of this strategy with adequately powered RCTs is warranted.
first_indexed 2024-12-23T11:55:05Z
format Article
id doaj.art-abf9ef28d5a545718d9f38d032c5f329
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-23T11:55:05Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-abf9ef28d5a545718d9f38d032c5f3292022-12-21T17:48:07ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015489710.1371/journal.pone.0154897Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.Hanyu ChenZhengjie ShenJiandong ChenHaowen ZhangXiaohu ChenOBJECTIVES:To assess the effectiveness and safety of Chinese herbal medicine (CHM) for the treatment of aspirin resistance (AR). METHODS:A comprehensive research of seven electronic databases was performed for comparative studies evaluating CHM for AR. Two authors independently extracted data and assessed the methodological quality of the included trials using the Cochrane risk of bias tool. Data wasere synthesized by using RevMan 5.3 software. (PROSPERO Registration #CRD42015020182). RESULTS:18 randomized controlled trials (RCTs) involving 1,460 patients were included. 15 RCTs reported significant difference in the reduction of platelet aggregation rate (PAR) induced by adenosine diphosphate (ADP) (P<0.05), and 11 reported significant effect of CHM plus aspirin to reduce PAR induced by arachidonic acid (AA) (P<0.05) compared with aspirin 100mg/d treatment. The pooling data of 3 RCTs showed the thromboxane B2 (TXB2) in patients with CHM plus aspirin versus aspirin were significantly reduced (Random Effect model (RE), Standard Deviation (SD) = -95.93, 95% Confidential Interval (CI)[-118.25,-73.61], P<0.00001). Subgroup analysis showed that TXB2 (Fixed Effect model (FE), SD = -89.23, 95%CI[-121.96,-56.49], P<0.00001) had significant difference in Tongxinluo capsule plus aspirin versus aspirin. 2 RCTs reported the clinical effective rate, and the meta-analysis result showed a significant difference in intervention and control group (FE, Relative Risk (RR) = 1.67, 95%CI[1.15, 2.42], P = 0.007<0.05). In 4 trials, CHM plus aspirin had better effects of reducing the reoccurrence of cerebral infarction than aspirin (FE, RR = 0.24, 95%CI [0.11, 0.49], P<0.0001). And one trial showed that CHM plus aspirin could decrease the National Institutes of Health Stroke Scale (NHISS) score (P<0.05) and increase the Barthel Index (BI) score (P<0.05). 4 trials stated that there were no adverse effects occurred in intervention group, and analysis showed significant difference of CHM or CHM plus aspirin in reducing the occurrence of adverse events (FE, RR = 0.22, 95%CI[0.13, 0.39], P<0.00001). 5 trials claimed that the CHM monotherapy and CHM adjunctive therapy for AR did not add the risk of bleeding (FE, RR = 0.50, 95%CI[0.20, 1.22], P = 0.13>0.05). CONCLUSIONS:CHM may be effective and safe as an alternative and collaborative therapy for AR. However, the current evidence and potential promising findings should be interpreted with caution due to poor and varying methodological quality of included studies and the heterogeneity of interventions. Thus, further exploration of this strategy with adequately powered RCTs is warranted.http://europepmc.org/articles/PMC4859478?pdf=render
spellingShingle Hanyu Chen
Zhengjie Shen
Jiandong Chen
Haowen Zhang
Xiaohu Chen
Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.
PLoS ONE
title Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.
title_full Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.
title_fullStr Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.
title_full_unstemmed Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.
title_short Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.
title_sort chinese herbal medicine for aspirin resistance a systematic review and meta analysis
url http://europepmc.org/articles/PMC4859478?pdf=render
work_keys_str_mv AT hanyuchen chineseherbalmedicineforaspirinresistanceasystematicreviewandmetaanalysis
AT zhengjieshen chineseherbalmedicineforaspirinresistanceasystematicreviewandmetaanalysis
AT jiandongchen chineseherbalmedicineforaspirinresistanceasystematicreviewandmetaanalysis
AT haowenzhang chineseherbalmedicineforaspirinresistanceasystematicreviewandmetaanalysis
AT xiaohuchen chineseherbalmedicineforaspirinresistanceasystematicreviewandmetaanalysis